LTRN vs. BTAI, LPTX, GRTS, PRPH, TNXP, ATAI, ENTA, XBIT, IMMP, and ME
Should you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include BioXcel Therapeutics (BTAI), Leap Therapeutics (LPTX), Gritstone bio (GRTS), ProPhase Labs (PRPH), Tonix Pharmaceuticals (TNXP), Atai Life Sciences (ATAI), Enanta Pharmaceuticals (ENTA), XBiotech (XBIT), Immutep (IMMP), and 23andMe (ME). These companies are all part of the "medical" sector.
Lantern Pharma (NASDAQ:LTRN) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.
Lantern Pharma has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.
Lantern Pharma has higher earnings, but lower revenue than BioXcel Therapeutics. Lantern Pharma is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Lantern Pharma has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -8,715.72%. Lantern Pharma's return on equity of -41.17% beat BioXcel Therapeutics' return on equity.
28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 6.9% of Lantern Pharma shares are held by insiders. Comparatively, 35.8% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
BioXcel Therapeutics received 226 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 67.23% of users gave BioXcel Therapeutics an outperform vote.
BioXcel Therapeutics has a consensus target price of $16.71, suggesting a potential upside of 823.44%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Lantern Pharma.
In the previous week, Lantern Pharma had 2 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 5 mentions for Lantern Pharma and 3 mentions for BioXcel Therapeutics. Lantern Pharma's average media sentiment score of 0.89 beat BioXcel Therapeutics' score of 0.69 indicating that Lantern Pharma is being referred to more favorably in the media.
Summary
Lantern Pharma beats BioXcel Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Lantern Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantern Pharma Competitors List
Related Companies and Tools
